The Oncology Institute, Inc.
Price Action
Technical Summary
EMERGING TRENDThe Oncology Institute, Inc. is attempting to emerge into an uptrend but lacks full moving average alignment. Relative strength is leading (RS Rating: 89), indicating clear outperformance against the broad market. Earnings growth of 90% provides fundamental context to the price action. However, price is extended 26% above the 50-day line, increasing the risk of a mean reversion.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $5.24 | +10.69% | ABOVE |
| 50 SMA | $4.59 | +26.27% | ABOVE |
| 100 SMA | $3.81 | +52.30% | ABOVE |
| 150 SMA | $3.66 | +58.67% | ABOVE |
| 200 SMA | $3.69 | +57.24% | ABOVE |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is TOI in an uptrend right now?
TOI has a trend score of 3/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 3 of 4 trend criteria are met.
Is TOI overbought or oversold?
TOI's RSI (14) is 60. The stock is in neutral territory, neither overbought nor oversold.
Is TOI outperforming the market?
TOI has a Relative Strength (RS) Rating of 89 out of 99. Yes, TOI is a market leader, outperforming 89% of all stocks over the past 12 months.
Where is TOI in its 52-week range?
TOI is trading at $5.80, which is 100% of its 52-week high ($5.81) and 100% above its 52-week low ($2.32).
How volatile is TOI?
TOI has a Beta of 1.77 and 52-week volatility of 79%. It's more volatile than the S&P 500 - expect bigger swings.